Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021
Deciphera Pharmaceuticals (NASDAQ: DCPH) will announce its fourth quarter and full year 2020 financial results on February 9, 2021. The company's management will hold a live conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide updates. Investors can access the call by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) with conference ID 5826559. The webcast will also be available on the company’s website.
- None.
- None.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021.
In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, February 9, 2021, to discuss the Company’s financial results and provide a corporate update.
The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 5826559. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005305/en/
FAQ
When will Deciphera Pharmaceuticals report its Q4 2020 financial results?
What time is Deciphera Pharmaceuticals' earnings call?
How can I access the conference call for Deciphera Pharmaceuticals?
Where can I find the webcast of Deciphera Pharmaceuticals' earnings call?
